159 related articles for article (PubMed ID: 36969074)
1. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report.
Liu Y; Du J; Zhang P; Meng W; Xiao H
Front Oncol; 2023; 13():1051786. PubMed ID: 36969074
[TBL] [Abstract][Full Text] [Related]
2. Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
He Y; Wang L; Li X; Zhang T; Song T; Zhang J; Yu Y; Chen S; Song H
Front Oncol; 2021; 11():596342. PubMed ID: 34113555
[TBL] [Abstract][Full Text] [Related]
3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
[TBL] [Abstract][Full Text] [Related]
5. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
6. Case Report: A management strategy and clinical analysis of primary squamous cell carcinoma of the colon.
Wu X; Su S; Wei Y; Hong D; Wang Z
Front Oncol; 2023; 13():1265421. PubMed ID: 37901330
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report.
Zhong L; Liu X; Li Z; Zhang X; Wang Y; Peng W
Front Oncol; 2021; 11():783158. PubMed ID: 35096582
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
Yang J; Xing P; Kong Y; Xu M; Zhang L
Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
[TBL] [Abstract][Full Text] [Related]
9. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
10. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF
Fang C; Lin J; Zhang T; Luo J; Nie D; Li M; Hu X; Zheng Y; Huang X; Xiao Z
Front Oncol; 2021; 11():652394. PubMed ID: 33987088
[TBL] [Abstract][Full Text] [Related]
12. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
13. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report.
Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T
Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Testing Overcomes Limitations of Comprehensive Genomic Profiling from Tumor Tissue.
Kumar A; Green M; Thacker J; Jeck WR; Strickler JH
Case Rep Oncol; 2023; 16(1):210-217. PubMed ID: 37064498
[TBL] [Abstract][Full Text] [Related]
16. Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer.
Lin H; Cao B
Dis Markers; 2022; 2022():3592990. PubMed ID: 35937946
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y
Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653
[TBL] [Abstract][Full Text] [Related]
18. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer.
Wang T; Shao Q; Xiao C; Liu L
Front Oncol; 2023; 13():1124730. PubMed ID: 36998454
[TBL] [Abstract][Full Text] [Related]
19. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
